Yang graduated at Shenyang Pharmaceutical University in 1986, after that he became a tutor and then lecturer in China Pharmaceutical University. During the period, he learned basic theories of Traditional Chinese Medicine at Nanjing University of Traditional Chinese Medicine, and conducted research in Gifu Pharmaceutical University in Japan as a visiting scholar
We have successfully achieved the preparation of intact solid lipid nano-vesicles that carry active pharmaceutical ingredients (API) and upon rehydration form liposomes with controlled drug release capability. To demonstrate this, solid lipid nano-vesicles were prepared by lyophilizing the mixture of liposomes combined with or without ligands such as DSS or CA9, entrapped water-soluble API such as albuterol or siRNA or insulin, mixed with cryo-protectant lactose and a plasticizer glycerol and water. Liposome structure, entrapped API and controlled release capability were retained after lyophilization and rehydration, and the in vivo delivery effectives were confirmed. Since solid lipid nano-vesicles are more adaptable than liposomes or other nanoparticles to a wide variety of APIs and dosage forms, our novel invention allows a much wider usage of liposome technology in numerous pharmaceutical, chemical and biological situations.
Lokesh has completed his masters in pharmacy from Lovely professional University, India and is currently pursuing his PhD in pharmacy from school of pharmacy, University of Waterloo, Canada. The project is funded by Punjab state council for science and technology and Lovely professional University, India as a part of his masters thesis. His current investigation in PhD is on non-viral ocular gene delivery for treating glaucoma.
Liquid self-emulsifying system is prepared by employing quality by design (QbD) using D-optimal mixture design. Solubility of bosentan monohydrate is determined in long chain and medium chain triglycerides, surfactants and co-surfactants. Optimal mixture design is used for setting various levels of constraints for the excipient concentrations in preparing liquid SMEDDS and response surfaces such as globule size, polydispersity index, dissolution efficiency and time for 85% drug release (t85%) are evaluated. Optimized batch containing bosentan monohydrate 62.5mg, capmul MCM (10.38%), labrasol/ cremophor EL 1:1 (56.0%), transcutol P (33.62%) is predicted by the design which is validated by droplet size, PDI, dissolution efficiency and t85% . Solid powder form is prepared by adsorbing liquid SMEDDS onto solid carrier material neusilin US2. In vitro dissolution studies, comparative dissolution profiles of prepared solid SMEDDS and marketed preparation ‘BOSENTAS’ are carried out and reported. Ex vivo permeation study using chicken intestine showed improved permeability up to 0.0649 µg/cm2/min. Droplet morphology and solid state characteristics are determined using TEM, XRD and SEM. Zeta potential of the system was found to be -1.89 mV. Reconstituted S-SMEDDS have droplet size of 77.97 nm compared to liquid SMEDDS droplet size 47.00 nm. TEM images revealed the spherical shape and least globule size while XRD peaks reveal the transformation of crystalline polymorph A2 state of drug to amorphous state in S-SMEDDS. SEM images validate the integrity in shape. This study demonstrates a strategic way for development of S-SMEDDS to a drug with low solubility by QbD approach.